Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study
Phase 3
N/A
N/A
N/A
N/A
Not Enrolling
Female
Metastatic Breast Cancer
Female
Metastatic Breast Cancer
Trial Information
Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study
Inclusion Criteria:
- Previous participation in study 971-ONC-0028-080.
Exclusion Criteria:
- Subjects who had not previously participated in study 971-ONC-0028-080.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Overall Survival
Outcome Description:
Overall survival in months measured from date of starting treatment in core study to date of death for any reason.
Outcome Time Frame:
Every 12 weeks up to 6 years
Safety Issue:
No
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
China: Ministry of Health
Study ID:
971-ONC-0028-094
NCT ID:
NCT01237327
Start Date:
November 2001
Completion Date:
December 2009
Related Keywords:
- Metastatic Breast Cancer
- Metastatic Breast Cancer
- Advanced
- Postmenopausal
- Exemestane vs Megestrol
- Breast Neoplasms
Name | Location |
|---|
